Ptc Therapeutics (PTCT) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $15.9 million.
- Ptc Therapeutics' Income from Continuing Operations rose 11490.43% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $489.4 million, marking a year-over-year increase of 19032.47%. This contributed to the annual value of -$625.6 million for FY2024, which is 1253.16% up from last year.
- Per Ptc Therapeutics' latest filing, its Income from Continuing Operations stood at $15.9 million for Q3 2025, which was up 11490.43% from -$64.8 million recorded in Q2 2025.
- In the past 5 years, Ptc Therapeutics' Income from Continuing Operations ranged from a high of $866.6 million in Q1 2025 and a low of -$328.2 million during Q4 2024
- In the last 5 years, Ptc Therapeutics' Income from Continuing Operations had a median value of -$128.6 million in 2021 and averaged -$84.7 million.
- In the last 5 years, Ptc Therapeutics' Income from Continuing Operations crashed by 9173.51% in 2021 and then skyrocketed by 104627.63% in 2025.
- Ptc Therapeutics' Income from Continuing Operations (Quarter) stood at -$143.3 million in 2021, then dropped by 21.82% to -$174.5 million in 2022, then plummeted by 40.05% to -$244.4 million in 2023, then crashed by 34.27% to -$328.2 million in 2024, then skyrocketed by 104.84% to $15.9 million in 2025.
- Its last three reported values are $15.9 million in Q3 2025, -$64.8 million for Q2 2025, and $866.6 million during Q1 2025.